A Phase I, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]EDP-938 Following a Single Oral Dose in Healthy Male Subjects
Latest Information Update: 21 Sep 2022
At a glance
- Drugs Zelicapavir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 21 Mar 2022 Status changed from recruiting to completed.
- 21 Jun 2021 New trial record